Aquestive is the undisputed leader in developing and delivering medications via film through our PharmFilm technology. Building on our success, we now have a robust CNS and complex molecule portfolio. We continuously strive to identify therapeutic areas where our proprietary technologies can help improve patient outcomes.
| Program | Molecule | Indication | Formulation | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Filed | Marketed |
|---|---|---|---|---|---|---|---|---|---|
| CNS Programs | |||||||||
| SYMPAZAN™ | clobazam | Lennox-Gastaut syndrome | |||||||
| AQST-203 | diazepam* | Acute Repetitive Seizures | |||||||
| AQST-117 | riluzole* | ALS | |||||||
| Complex Molecule Programs | |||||||||
| AQST-108 | epinephrine* | Anaphylaxis | |||||||
| AQST-305 | octreotide* | Acromegaly / Carcinoid Syndrome | |||||||
| Partnered Programs | |||||||||
| Suboxone (Partner: Indivior) | buprenorphine / naloxone | Opioid Dependence | |||||||
| Zuplenz (Partner: Midatech) | ondansetron | CINV / PINV | |||||||
| APL-130277 (Partner: Sunovion) | apomorphine* | Parkinson’s Disease | |||||||
| AQST-119 | tadalafil* | Erectile Dysfunction / BPH | |||||||
*Assets are currently in development. Final indication is subject to the completion of trials; assessment of clinical and safety data; plus the filing, review, and evaluation by FDA and regulatory authorities.
Current as of March 2019
CNS Programs
SYMPAZAN™
+
–
Molecule: clobazam
Indication: Lennox-Gestaut syndrome
Phase: marketed
AQST-203
+
–
Molecule: diazepam*
Indication: acute repetitive seizures
Phase: 3
AQST-117
+
–
Molecule: riluzole*
Indication: ALS
Phase: filed
Complex Molecule Programs
AQST-108
+
–
Molecule: epinephrine*
Indication: Anaphalaxis
Phase: 1
AQST-305
+
–
Molecule: octreotide*
Indication: Acromegaly / Carcinoid Syndrome
Phase: pre-clinical
Partnered Programs
Suboxone
+
–
Molecule: buprenorphine / naloxone
Indication: Opioid Dependence
Phase: marketed
Partner: Indivior
Zuplenz
+
–
Molecule: ondansetron
Indication: CINV / PINV
Phase: marketed
Partner: Midatech
APL-130277
+
–
Molecule: apomorphine*
Indication: Parkinson’s Disease
Phase: 3
Partner: Sunovion
AQST-119
+
–
Molecule: tadalafil*
Indication: Erectile Dysfunction / BPH
Phase: filed
Partner: Actively pursuing partnerships
*Assets are currently in development. Final indication is subject to the completion of trials; assessment of clinical and safety data; plus the filing, review, and evaluation by FDA and regulatory authorities.
Current as of March 2019
Latest comments
Sorry, the comment form is closed at this time.